SCHEMBL29457333

SCHEMBL29457333

CCO/C=C(\C(=O)OCC)C(=O)c1cc(Cl)c(Cl)nc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.36
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
MAPT P10636 6/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GLO1 Q04760 1/20 0.34
LMNA P02545 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
S1PR4 O95977 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19987096 1.00 NPSR1 (0.36) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL29457332 1.00 NPSR1 (0.36) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL21174014 0.88 KEAP1 (0.33) MAPTATMTSHRSMN1; SMN2ALDH1A1
SCHEMBL29457327 0.87 KEAP1 (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL7172244 0.87 KEAP1 (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL4458375 0.87 KEAP1 (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL29733883 0.87 KEAP1 (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL7012803 0.87 KEAP1 (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL2083262 0.82 MEN1 (0.39) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL2083261 0.82 MEN1 (0.39) NPSR1MEN1KMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 US disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 NPSR1 1072/4885MEN1 3502/4885KMT2A 2845/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 NPSR1 1072/4885MEN1 3502/4885KMT2A 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.